Arcutis Biotherapeutics (ARQT) Share-based Compensation (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Share-based Compensation of $10.7 million for Q1 2026, up 9.33% year-over-year from $9.8 million in Q1 2025, and up 161.41% quarter-over-quarter from -$17.4 million in Q3 2025.
Arcutis Biotherapeutics (ARQT) Share-based Compensation (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $10.7 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 9.33% year-over-year to $10.7 million; the TTM figure through Mar 2026 stood at $3.8 million (up 1596.03% YoY), while the FY2025 annual figure was $2.9 million, changed N/A from the prior year.
- Share-based Compensation for Q1 2026 stood at $10.7 million, up from -$17.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $12.5 million in Q2 2024, with the low at -$32.3 million in Q4 2024.
- The 5-year median for Share-based Compensation is $9.6 million (2023), against an average of $2.9 million.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation surged 86.54% in 2022, then slumped 424.44% in 2023.
- Arcutis Biotherapeutics' Share-based Compensation stood at $9.3 million in 2022, then plunged by 424.44% to -$30.1 million in 2023, then slipped by 7.59% to -$32.3 million in 2024, then soared by 46.16% to -$17.4 million in 2025, then surged by 161.41% to $10.7 million in 2026.
- Business Quant data shows ARQT's Share-based Compensation at $10.7 million in Q1 2026, -$17.4 million in Q3 2025, and $10.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 12.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.76 Mn |
| Jun 30, 2026 | 12.76 Mn |
| Mar 31, 2026 | 10.69 Mn |
| Mar 31, 2026 | 10.69 Mn |
| Sep 30, 2025 | -17.41 Mn |
| Sep 30, 2025 | -17.41 Mn |
| Jun 30, 2025 | 10.49 Mn |
| Jun 30, 2025 | 10.49 Mn |
| Mar 31, 2025 | 9.78 Mn |
| Mar 31, 2025 | 9.78 Mn |
| Dec 31, 2024 | -32.34 Mn |
| Dec 31, 2024 | -32.34 Mn |
| Sep 30, 2024 | 9.78 Mn |
| Sep 30, 2024 | 9.78 Mn |
| Jun 30, 2024 | 12.52 Mn |
| Jun 30, 2024 | 12.52 Mn |
| Mar 31, 2024 | 10.03 Mn |
| Mar 31, 2024 | 10.03 Mn |
| Dec 31, 2023 | -30.06 Mn |
| Dec 31, 2023 | -30.06 Mn |